|
|
by Movik, Espen, Hamidi, Vida, Aaserud, Morten, Neilson, Aileen Rae
Published 2008
“... The evidence base regarding the cost-effectiveness of cetuximab is, at the time of writing, weak, particularly...”Published 2008
Norwegian Knowledge Centre for the Health Services